Table 4. Pathological results. CRT, chemoradiotherapy.
| LPLD group (n=25) (%) |
No LPLD group (n=92) (%) |
p | ||
|---|---|---|---|---|
| Pathological tumor stage, n (%) |
0.382 | |||
| pT0 | 4 (16.0) | 20 (21.7) | ||
| pT1 | 2 (8.0) | 6 (6.5) | ||
| pT2 | 7 (28.0) | 29 (31.5) | ||
| pT3 | 8 (32.0) | 33 (35.9) | ||
| pT4 | 4 (16.0) | 4 (4.3) | ||
| Pathological node stage, n (%) |
0.262 | |||
| pN0 | 15 (60.0) | 70 (76.1) | ||
| pN1 | 8 (32.0) | 16 (17.4) | ||
| pN2 | 2 (8.0) | 6 (6.5) | ||
| Mean harvested lymph node dissection (min– max) |
13.5 (5–29) | 8.1 (2–19) | 0.000 | |
| Lateral pelvic lymph node metastases, n (%) |
||||
| Positive | 4 (16.0) | - | ||
| Negative | 22 (84.0) | - | ||
| Left | 3 (12.0) | |||
| Right | 1 (4.0) | |||
| Circumferential resection margin, n (%) |
0.065 | |||
| Positive | 3 (12.0) | 2 (2.2) | ||
| Negative | 22 (88.0) | 90 (97.8) | ||
| Tumor differentiation (n) | 0.399 | |||
| Well | 0 | 3 | ||
| Moderate | 18 | 64 | ||
| Poor or mucinous | 5 | 9 | ||
| No tumor cell after CRT | 2 | 16 |